Skip to main content
. Author manuscript; available in PMC: 2021 Nov 16.
Published in final edited form as: JID Innov. 2021 Sep 2;1(3):100037. doi: 10.1016/j.xjidi.2021.100037

Table 1.

Demographic and clinical characteristics of 15 sclerotic cGVHD patients.

cGVHD Subjects (n=15) Subject ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Summary1
Demographics2 Age 55 52 40 28 72 59 47 47 71 60 14 65 60 35 70 55 [40–65]
Race C C C C C C C C C C C C C C C 100% C
Sex M M M F M M M F F M M M M M M 80% M
BMI 24 24 27 14 31 17 23 34 21 20 22 33 18 23 32 23 [20–31]
Disease Characteristics3 Disease Histology AML MDS MM HL ALL AML NHL ALL AML MDS AML AML NHL ALL CLL 33% AML
20% ALL
13% NHS
13% MDS
7% MM
7% HL
7% CLL
Transplant Characteristics4 Transplant Source BM PB PB PB PB PB PB BM PB PB PB PB PB PB - 12/14 PB
2/14 BM
cGVHD Characteristics at Study Entry5 NIH Score BSA Involvement 3 3 2 3 2 3 1 2 1 2 3 1 2 1 - 4/14 NIH 1
5/14 NIH 2
5/14 NIH 3
NIH Score Skin Feature 3 3 3 3 3 3 3 3 2 3 3 2 3 3 2 80% NIH 3
20% NIH 2
MyotonPRO Session Days from HCT6 1676 4604 1084 1908 1169 2030 2575 4429 1256 1119 1339 3660 1061 1686 2132 1686 [1169–2575]
1

Values are shown as median [interquartile range] for continuous variables and n (%) for categorical variables

2

Demographics: C: Caucasian, M: Male, F: Female

3

Disease characteristics: AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, CLL: chronic lymphoblastic leukemia, MDS: myelodysplastic disorder, MM: multiple myeloma, NHL: non-Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma

4

Transplant characteristics: PB: peripheral blood, BM: bone marrow

5

NIH Score BSA involvement: 1: 1–18%, 2:19–50%, 3: >50%; NIH Score Skin Feature: 2: superficial sclerosis, 3: deep sclerosis

6

Days from HCT: days between hematopoietic cell transplantation and MyotonPRO measurement session